$999.00
Quantity: ~1M viable cells
CIRM Line ID: CW50065
Disease: Healthy Donor
Gender: Female
Sampled age: 74
Ethinicity: Caucasian, not Latino
Description
Quantity: ~1M viable cells
CIRM Line ID: CW50065
Disease: Healthy Donor
Gender: Female
Sampled age: 74
Race: Caucasian, not Latino
Donor data
Demographic (source: CIRM) | Description | CONTROL: NO COGNITIVE DECLINE (BASED ON COGNITIVE ASSESSMENT) | CONTROL: NON-DIABETIC WITHOUT AMD/DR/POAG (SELF-REPORTED) | CHRONIC LUNG DISEASE (SELF-REPORTED): COPD/EMPHYSEMA |
Affected Status | No | |
Product | iPSC | |
Source | PBMC | |
Sex | Female | |
Age at Sampling | 74 YR | |
Race | Caucasian | |
Ethnicity | Not Hispanic or Latino | |
Publications Cited | 0 | |
dbGap | No | |
Biopsy Source | Blood | |
Collection | Alzheimer’s Disease,Blinding Eye Diseases,Control,Lung Diseases | |
Remarks | Additional Clone Available please contact�[email protected] | |
Cell Type | Stem Cell | |
Tissue Type | Induced pluripotent stem cell | |
Transformant | Episomal | |
Species | sapiens | |
Common Name | human | |
Detailed Clinical Data | false | |
Clinical data (source: CIRM) | CognitiveSharedControl | CognitiveSharedControl |
History_of_significant_memory_changes_in_the_past_ | No | |
History_of_major_depression_or_psychiatric_illness | No | |
History_of_seizures_alcohol_or_drug_abuse | No | |
Montreal_Cognitive_Assessment_(MOCA)_score_>_25/30 | Yes | |
Parent_or_sibling_with_Alzheimers_Disease_with_ons | No | |
OphthalmicSharedControl | OphthalmicSharedControl | |
Glaucoma | No | |
Age-Related_Macular_Degeneration | No | |
Diabetic | No | |
Diabetic_retinopathy | No | |
Family_history_of_eye_diseases | Don’t know | |
PulmonarySharedControl | PulmonarySharedControl | |
Smoking_Status | Former | |
Form_of_Tobacco | Cigarettes | |
Cigarettes_Average_smoked_per_day_quantity | 15 | |
Cigarettes_Average_smoked_per_day_units | Cigarettes | |
Age_Started | 21 | |
Age_Quit | 55 | |
History_of_chronic_lung_disease | Yes | |
Chronic??lung_disease(s)_present | COPD/Emphysema | |
Experienced_a_cough_at_least_4_days_a_week_for_at_ | Yes | |
Experienced_breathlessness_that_limits_ability_to_ | Vigorous activity (hiking, jogging, heavy lifting, etc) | |
Used_or_been_prescribed_oxygen | No | |
Had_a_transplant_(bone_marrow_peripheral_stem_cell | No | |
Active_cancer_or_cancer_diagnosis_in_the_past_2_ye | No | |
Family_history_of_pulmonary_fibrosis | No |
- Users do not need any additional license for the use of these differentiated cells even when cells are used for high throughput screening or drug discovery.
- All donor consents include statements on the following:
- Testing the cells’ DNA (this is referred to as the cell’s genetic code or sequence) and making the information known to other researchers
- Changing some of the genetic code or sequence within these cells
- Using cells to test or select drugs to treat disease
- Transplanting cells or resulting products to humans or animals
Distributing cells widely (nationally and internationally) for research, training or commercial medical product development - Future research and uses unforeseen at this time
- Donors were screened and negative for HIV, HBV, and HCV. Donors under the age of 18 could opt out of HIV testing; all HCV-positive donors submitted skin punches, not peripheral blood, and were not screened for any infectious agents due to small volume of blood present in punches.
- Human induced pluripotent stem cells were established by non-integrating episomal reprogramming. Reprogramming and quality control were performed by Cellular Dynamics International.
Characteristics
Please refer this page for some characteristics data.